目的：双打击淋巴瘤(DHL)或三打击淋巴瘤(THL)是弥漫大B细胞淋巴瘤(DLBCL)中非常罕见且难治的亚型，目前尚无针对DHL或THL的有效疗法。维奈托克联合布鲁顿酪氨酸激酶(BTK)抑制剂在治疗其他非霍奇金淋巴瘤中发挥的作用驱使我们去探究其在DLBCL中的疗效。方法：回顾性分析2020年11月转诊至东南大学附属中大医院的1例原发于小肠的THL患者的治疗经过。结果：该患者为原发性小肠THL，于外院行肠淋巴瘤切除术，转入我院接受R2-CHOP方案和R2-EPOCH(R2-CHOP+依托泊苷)方案各1个疗程化疗后出现疾病进展。之后患者接受了两个疗程的维奈托克联合泽布替尼疗法，复查胸腹部CT示病灶缩小、减少，疗效评价为部分缓解。结论：使用维奈托克联合BTK抑制剂疗法治疗THL并取得了良好疗效，安全性亦良好。这给对传统化疗方案不敏感的THL患者提供了新的治疗选择。

[1] TILLY H,GOMES DA SILVA M,VOTOLO U,et al.Diffuse large B-cell lymphoma(DLBCL):ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2015,26(Suppl 5):v116-v125.
[2] RADASZKIEWICZ T,DRAGOSICS B,BAUER P.Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue:factors relevant to prognosis[J].Gastroenterology,1992,102(5):1628-1638.
[3] LIANG R,TODD D,CHAN T K,et al.Prognostic factors for primary gastrointestinal lymphoma[J].Hematol Oncol,1995,13(3):153-163.
[4] HANS C P,WEISENBURGER D D,GREINER T C,et al.Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J].Blood,2004,103(1):275-282.
[5] ALIZADEH A A,EISEN M B,DAVIS R E,et al.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J].Nature,2000,403(6769):503-511.
[6] RIEDELL P A,SMITH S M.Double hit and double expressors in lymphoma:Definition and treatment[J].Cancer,2018,124(24):4622-4632.
[7] HORN H,ZIEPERT M,BECHER C,et al.MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma[J].Blood,2013,121(12):2253-2263.
[8] 郭慧玲,吴涛,白海.双打击淋巴瘤与双表达淋巴瘤的研究进展[J].白血病·淋巴瘤,2020,05):307-309.
[9] SNUDERL M,KOLMAN O K,CHEN Y B,et al.B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma[J].Am J Surg Pathol,2010,34(3):327-340.
[10] DAVIDS M S,ROBERTS A W,SEYMOUR J F,et al.Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma[J].J Clin Oncol,2017,35(8):826-833.
[11] DAVIS R E,NGO V N,LENZ G,et al.Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma[J].Nature,2010,463(7277):88-92.
[12] SASI B K,MARTINES C,XERXA E,et al.Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma[J].Leukemia,2019,33(10):2416-2428.
[13] 李效营,张学美.双打击淋巴瘤的诊疗进展[J].医学综述,2017,23(24):4824-4828.
[14] 严红,姚福生,梁虹,等.不同亚型DLBCL患者bcl-2表达对利妥昔单抗疗效的影响[J].东南大学学报(医学版),2017,36(1):90-93.
[15] CHAMULEAU M E D,BURGGRAAFF C N,NIJLAND M,et al.Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide:results of a multicenter HOVON phase II trial[J].Haematologica,2020,105(12):2805-2812.
[16] TARANTELLI C,ZHANG L,CURTI E,et al.The Bruton tyrosine kinase inhibitor zanubrutinib(BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents[J].Haematologica,2019,104(7):e307-e309.
[17] DUNLEAVY K,FANALE M A,ABRAMSON J S,et al.Dose-adjusted EPOCH-R(etoposide,prednisone,vincristine,cyclophosphamide,doxorubicin,and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement:a prospective,multicentre,single-arm phase 2 study[J].Lancet Haematol,2018,5(12):e609-e617.
[18] KONOPLEVA M,CONTRACTOR R,TSAO T,et al.Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia[J].Cancer Cell,2006,10(5):375-388.
[19] UCHIDA A,ISOBE Y,ASANO J,et al.Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with MYC and BCL2 rearrangements[J].Haematologica,2019,104(7):1417-1421.
[20] CINAR M,ROSENFELT F,ROKHSAR S,et al.Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas[J].Leuk Res,2015,39(7):730-738.
[21] WINTER A M,LANDSBURG D J,MATO A R,et al.A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib[J].Blood,2017,130(14):1676-1679.
[22] ZHAO X,BODO J,SUN D,et al.Combination of ibrutinib with ABT-199:synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK,AKT and BCL2 pathways[J].Br J Haematol,2015,168(5):765-768.
[23] LI Y,BOUCHLAKA M N,WOLFF J,et al.FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma[J].Oncogene,2016,35(48):6223-6234.
[24] TAM C S,ANDERSON M A,POTT C,et al.Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma[J].N Engl J Med,2018,378(13):1211-1223.
[25] JAIN N,KEATING M,THOMPSON P,et al.Ibrutinib and venetoclax for first-line treatment of CLL[J].N Engl J Med,2019,380(22):2095-2103.
[26] KUO H P,EZELL S A,SCHWEIGHHOFER K J,et al.Combination of Ibrutinib and ABT-199 in Diffuse large B-cell lymphoma and follicular lymphoma[J].Mol Cancer Ther,2017,16(7):1246-1256.